JP2022516006A - 修飾オルソポックスウイルスベクター - Google Patents

修飾オルソポックスウイルスベクター Download PDF

Info

Publication number
JP2022516006A
JP2022516006A JP2021535833A JP2021535833A JP2022516006A JP 2022516006 A JP2022516006 A JP 2022516006A JP 2021535833 A JP2021535833 A JP 2021535833A JP 2021535833 A JP2021535833 A JP 2021535833A JP 2022516006 A JP2022516006 A JP 2022516006A
Authority
JP
Japan
Prior art keywords
nucleotide sequence
promoter
nucleic acid
gene
transgene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021535833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516006A5 (https=
JPWO2020124274A5 (https=
Inventor
ジョン シー． ベル，
マイケル エス． ハ，
マシュー ワイ． タン，
エイドリアン ペリン，
キャロライン ジェイ． ブライトバッハ，
マイケル エフ． バージェス，
スティーブン エイチ． バーンスタイン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Turnstone Biologics Corp
Original Assignee
Turnstone Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turnstone Biologics Corp filed Critical Turnstone Biologics Corp
Publication of JP2022516006A publication Critical patent/JP2022516006A/ja
Publication of JP2022516006A5 publication Critical patent/JP2022516006A5/ja
Publication of JPWO2020124274A5 publication Critical patent/JPWO2020124274A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021535833A 2018-12-21 2019-12-20 修飾オルソポックスウイルスベクター Pending JP2022516006A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862784372P 2018-12-21 2018-12-21
US62/784,372 2018-12-21
US201962872699P 2019-07-10 2019-07-10
US62/872,699 2019-07-10
US201962930524P 2019-11-04 2019-11-04
US62/930,524 2019-11-04
PCT/CA2019/051899 WO2020124274A1 (en) 2018-12-21 2019-12-20 Modified orthopoxvirus vectors

Publications (3)

Publication Number Publication Date
JP2022516006A true JP2022516006A (ja) 2022-02-24
JP2022516006A5 JP2022516006A5 (https=) 2023-01-04
JPWO2020124274A5 JPWO2020124274A5 (https=) 2023-01-04

Family

ID=71100021

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535833A Pending JP2022516006A (ja) 2018-12-21 2019-12-20 修飾オルソポックスウイルスベクター
JP2021535804A Pending JP2022514420A (ja) 2018-12-21 2019-12-20 修飾オルソポックスウイルスベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021535804A Pending JP2022514420A (ja) 2018-12-21 2019-12-20 修飾オルソポックスウイルスベクター

Country Status (18)

Country Link
US (2) US20220380799A1 (https=)
EP (2) EP3898997A4 (https=)
JP (2) JP2022516006A (https=)
KR (2) KR20210132003A (https=)
CN (2) CN113661246A (https=)
AU (2) AU2019410148A1 (https=)
BR (2) BR112021012078A2 (https=)
CA (2) CA3124287A1 (https=)
CL (1) CL2021001646A1 (https=)
CO (1) CO2021009354A2 (https=)
EC (1) ECSP21053474A (https=)
IL (2) IL284180A (https=)
MX (2) MX2021007439A (https=)
PE (1) PE20212307A1 (https=)
PH (1) PH12021551436A1 (https=)
SG (1) SG11202106460XA (https=)
TW (1) TW202039851A (https=)
WO (2) WO2020124274A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3778881A1 (en) 2016-01-08 2021-02-17 Replimune Limited Modified oncolytic virus
US12350303B2 (en) 2017-02-03 2025-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Oncolytic virus therapy
MX2020007010A (es) 2018-01-05 2020-12-10 Ottawa Hospital Res Inst Vectores modificados de orthopoxvirus.
WO2021102307A1 (en) * 2019-11-20 2021-05-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccinia viruses and methods for using vaccinia viruses
JP6915792B1 (ja) * 2020-10-01 2021-08-04 国立大学法人鳥取大学 広範囲遺伝子欠損を有する腫瘍溶解性ワクシニアウイルス
WO2023106839A1 (ko) * 2021-12-07 2023-06-15 재단법인 아산사회복지재단 Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도
AU2023207821A1 (en) * 2022-01-17 2024-09-05 Nouscom Ag Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment
CN119677861A (zh) * 2022-06-10 2025-03-21 特兰斯吉恩股份有限公司 表达白介素-12的重组病毒
CA3260631A1 (en) * 2022-07-08 2024-01-11 Viromissile, Inc. Oncolytic and recombinant vaccine viruses and their methods of use
KR20250044313A (ko) * 2022-07-27 2025-03-31 아스트라제네카 아베 Pd-1/pd-l1 저해제와 인터루킨-12를 발현하는 재조합 바이러스의 조합물
CN115947797B (zh) * 2022-08-02 2024-07-05 青岛硕景生物科技有限公司 猴痘病毒重组抗原及其应用
WO2024130212A1 (en) 2022-12-16 2024-06-20 Turnstone Biologics Corp. Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors
CN115927215B (zh) * 2023-01-18 2025-10-17 中国医学科学院病原生物学研究所 一种定向减毒的痘苗病毒疫苗
CN116200349A (zh) * 2023-01-18 2023-06-02 中国医学科学院病原生物学研究所 一种基于改良痘苗病毒天坛株的新型冠状病毒疫苗
CN118240879A (zh) * 2023-11-01 2024-06-25 上海市重大传染病和生物安全研究院 骨架质粒、重组质粒以及猴痘病毒颗粒和应用
WO2026047314A1 (en) * 2024-08-28 2026-03-05 University Of Surrey Recombinant vector

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004034995A2 (en) * 2002-10-15 2004-04-29 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods and reagents for inducing immunity
JP2011078427A (ja) * 2002-08-12 2011-04-21 Jennerex Inc ポックスウイルスおよび癌に関する方法および組成物
JP2017522025A (ja) * 2014-07-16 2017-08-10 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス
JP2018533970A (ja) * 2015-09-09 2018-11-22 北京▲錘▼特生物科技有限公司 改変型インターロイキン１２および腫瘍の治療のための医薬品の製造におけるその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0992584A3 (en) * 1993-05-19 2000-06-07 Schering Corporation Purified mammalian FLT3 ligands and agonists and antagonists thereof
CA2705869C (en) * 2007-11-19 2012-10-30 Philippe Erbs Poxviral oncolytic vectors
DK3036329T3 (da) * 2013-08-22 2021-01-11 Univ Pittsburgh Commonwealth Sys Higher Education Immunonkolytiske terapier
WO2018049261A1 (en) * 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
MX2020007010A (es) * 2018-01-05 2020-12-10 Ottawa Hospital Res Inst Vectores modificados de orthopoxvirus.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011078427A (ja) * 2002-08-12 2011-04-21 Jennerex Inc ポックスウイルスおよび癌に関する方法および組成物
WO2004034995A2 (en) * 2002-10-15 2004-04-29 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods and reagents for inducing immunity
JP2017522025A (ja) * 2014-07-16 2017-08-10 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス
JP2018533970A (ja) * 2015-09-09 2018-11-22 北京▲錘▼特生物科技有限公司 改変型インターロイキン１２および腫瘍の治療のための医薬品の製造におけるその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. GEN. VIROL., vol. 96, no. 11, JPN6023050045, November 2015 (2015-11-01), pages 3326 - 3337, ISSN: 0005354824 *

Also Published As

Publication number Publication date
CA3124301A1 (en) 2020-06-25
JP2022514420A (ja) 2022-02-10
BR112021012078A2 (pt) 2021-08-31
IL284180A (en) 2021-08-31
CO2021009354A2 (es) 2021-11-19
EP3898998A1 (en) 2021-10-27
EP3898997A1 (en) 2021-10-27
WO2020124273A1 (en) 2020-06-25
AU2019404639A1 (en) 2021-08-12
EP3898998A4 (en) 2022-10-05
CL2021001646A1 (es) 2022-02-18
KR20210132002A (ko) 2021-11-03
WO2020124274A1 (en) 2020-06-25
MX2021007439A (es) 2021-08-05
PE20212307A1 (es) 2021-12-10
EP3898997A4 (en) 2022-11-16
CN113661246A (zh) 2021-11-16
US20220380799A1 (en) 2022-12-01
US20220056480A1 (en) 2022-02-24
TW202039851A (zh) 2020-11-01
PH12021551436A1 (en) 2021-12-06
KR20210132003A (ko) 2021-11-03
CA3124287A1 (en) 2020-06-25
SG11202106460XA (en) 2021-07-29
AU2019410148A1 (en) 2021-08-12
BR112021011730A2 (pt) 2021-08-31
ECSP21053474A (es) 2021-11-18
CN113454231A (zh) 2021-09-28
MX2021007438A (es) 2021-09-21
IL284188A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
JP2022516006A (ja) 修飾オルソポックスウイルスベクター
JP7312412B2 (ja) 改変オルトポックスウイルスベクター
JP7025339B2 (ja) 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
JP7066812B2 (ja) 癌を治療するための治療用組成物及び使用方法
JP2024026075A (ja) 改変ワクシニアベクター
WO2019196617A1 (zh) 重组溶瘤病毒组合物及其用途
CN118871455A (zh) 改进的痘苗病毒载体
JP2022512595A (ja) 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法
EP2680867B1 (en) Enhanced tumor therapy by tumor stem cell targeted oncolytic viruses
HK40088421A (en) Modified vaccinia vectors
JP2025503721A (ja) がん治療用免疫刺激タンパク質をコードする組換えオルソポックスウイルスベクター
Suryadevara CAR T-cell Immunotherapy for Brain Tumors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240625